We’re a partner that can help you make a real difference for those affected by cancer.
Finding new treatment paths for difficult-to-treat cancers
Omico’s landmark Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) aims to open up new options for patients with difficult-to-treat, advanced and metastatic cancers.
Matching patients to biomarker-led clinical trials
Through our Cancer Screening Project (CaSP) we’re performing comprehensive genomic profiling for cancer patients with unmet clinical need to match them to clinical trials or other care pathways.
Matching molecular changes to targeted therapy
Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.
Identifying genetic basis of cancer risk
We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.
Improving surveillance of multi-organ cancer
Our Surveillance study in Multi-Organ Cancer-prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high risk of multi-organ cancer.
Information, resources and support networks
Rare Cancer Australia
Rare Cancer Australia (RCA) provides support and advocacy for patients wishing to participate in Omico programs. If you or your family need advice or help, a place to learn or simply someone to listen, RCA can help.Visit the RCA website
If you are aged from 12 to 25 and your world has been turned upside down by cancer, Canteen provides support as well as someone to talk to.Visit the Canteen website